Dr Craig Gedye
“It’s incredibly frustrating to watch a treatment help one person and fail completely in another. But this is the reality we must face - cancer is different in every person. Recognising this challenge also gives us an opportunity to improve outcomes – person-by-person, one-by-one. It is this challenge that inspires me and continues to motivate my work”.
Dr Craig Gedye is a physician/scientist, dual trained as a medical oncologist and as a basic science cancer researcher. Based at the Calvary Mater Newcastle, he is inspired by working for patients with kidney, prostate, testis, bladder and brain cancer and melanoma, while also undertaking clinical, translational and basic cancer research at the University of Newcastle/HMRI.
Dr Gedye’s research focuses on complexity in cancer, with a particular interest in understanding "intratumoural heterogeneity". After training in New Zealand he moved to Canada in 2008, undertaking a Postdoctoral Fellowship at the University of Toronto and Princess Margaret Cancer Centre. There, he simultaneously undertook a Clinical Fellowship in melanoma as the new class of cancer drugs, the checkpoint immunotherapy antibodies, came into the clinic.
Dr Gedye returned to Australia in February 2014 to pursue research interests at the Calvary Mater Newcastle, University of Newcastle and HMRI.
He is leading the ANZUP Cancer Trials Renal Cancer subcommittee, and is a member of the Mark Hughes Scientific Advisory Committee, HNEHLD Clinical Trials Ethics Subcommittee, ANZUP Cancer Trials Scientific Advisory Committee, Advisory Board member for Kidney Health Australia, HCRA Biomarkers Flagship Program Steering Committee and HCB Management Committee.
To learn more about other speaker?